Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations Floranne C. Ernste, MD, Ann M. Reed, MD Mayo Clinic Proceedings Volume 88, Issue 1, Pages 83-105 (January 2013) DOI: 10.1016/j.mayocp.2012.10.017 Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 1 Initial management of uncomplicated, newly diagnosed idiopathic inflammatory myopathy in adult patients. IBW = ideal body weight; MTX = methotrexate. Mayo Clinic Proceedings 2013 88, 83-105DOI: (10.1016/j.mayocp.2012.10.017) Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 2 Treatment of idiopathic inflammatory myopathy refractory to conventional therapy or with severe organ-threatening manifestations such as interstitial lung disease, severe dysphagia with weight loss, severe weakness, or cardiomyopathy. CYC = cyclophosphamide; CSA = cyclosporine A; IV = intravenous; IVIG = intravenous immunoglobulin; JDM = juvenile dermatomyositis. Mayo Clinic Proceedings 2013 88, 83-105DOI: (10.1016/j.mayocp.2012.10.017) Copyright © 2013 Mayo Foundation for Medical Education and Research Terms and Conditions